With pan-RAF drug from Take­da, Day One un­veils its first pe­di­atric brain can­cer da­ta. And the mar­ket loves it

Day One Bio­phar­ma­ceu­ti­cals has gath­ered the first cut of Phase II da­ta on its quest to repo­si­tion a Take­da drug as a treat­ment for pe­di­atric can­cer, and in­vestors are ev­i­dent­ly thrilled.

With an over­all re­sponse rate of 64% among the first 25 pa­tients who have a type of brain tu­mor called re­cur­rent or pro­gres­sive low-grade glioma (pLGG), Day One said late Sun­day the re­sults bode well for the rest of the FIRE­FLY-1 study, which fea­tures a reg­is­tra­tional co­hort out of three arms. That co­hort is ful­ly en­rolled and ex­pect­ed to get to a read­out in 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER